CELU compared with ATHE: revenue, margins and what each company keeps, and the suppliers and customers both name

CELUCelularity Inc

Mkt capRevenueRevenue

ATHEAlterity Therapeutics Ltd

Mkt capRevenueRevenue

Compare

CELUCelularity Inc

ATHEAlterity Therapeutics Ltd

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Revenue flow

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Price

rebased to 0%

CELU, solidATHE, dashed

Supply-chain overlap

Revenue flow

CELU: latest quarter not drawable. ATHE: latest quarter not drawable.Method ›

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only CELU 0

None

Shared 0

No disclosed counterparties: CELU.

Only ATHE 5

—JonesTrading Institutional Servicesunlistedsupplier

—PricewaterhouseCoopersunlistedsupplier

—The Bank of New York Mellon (BNYM)unlistedsupplier

—The University of Melbourne's Bio21 Molecular Science and Biotechnology Instituteunlistedsupplier

1 more · ATHE chain ›

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

CELUCelularity Inc

0.81▼−4.96%· post 0.81

Mkt cap$26.0MRevenue$4MQ1 FY26

ATHEAlterity Therapeutics Ltd

2.17▼−2.84%· post 2.16

ClosedOct 30 '26

Mkt cap$783,032Revenue—

Compare

ClosedOct 30 '26

CELUCelularity Inc

ATHEAlterity Therapeutics Ltd

0.81▼−4.96%post 0.81

Price

2.17▼−2.84%post 2.16

$26.0M

Mkt cap

$783,032

Q1 FY26$4M

Revenue

—

CELU0.81▼−4.96%vsATHE2.17▼−2.84%ClosedOct 30 '26